Sabeluzole data

The drug produced statistically significant slowing of cognitive deterioration, as measured by a clinical test, in a Phase II trial. The results were demonstrated in 108 patients with probable Alzheimer's, given one of two doses of the drug or placebo for 48 weeks. ...